Thyrocare Technologies Ltd's Q4FY25 Quarter Results
- 24 Apr 2025
Result Summary
- Thyrocare Technologies Ltd reported a 7.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 13.0%.
- Its expenses for the quarter were down by 5.1% QoQ and up 9.8% YoY.
- The net profit decreased 9.3% QoQ and increased 37.6% YoY.
- The earnings per share (EPS) of Thyrocare Technologies Ltd stood at 3.5 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 157.74 | 169.93 | 139.58 | -7.2% | 13.0% |
Total Expenses | 134.62 | 141.85 | 122.66 | -5.1% | 9.8% |
Profit Before Tax | 23.12 | 28.08 | 16.92 | -17.7% | 36.6% |
Tax | 5.72 | 8.97 | 4.75 | -36.2% | 20.4% |
Profit After Tax | 17.18 | 18.95 | 12.49 | -9.3% | 37.6% |
Earnings Per Share | 3.50 | 3.60 | 2.40 | -2.8% | 45.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Thyrocare Technologies Ltd is a leading diagnostic laboratory services company in India, known for its extensive network of diagnostic centers and its focus on preventive healthcare services. Established with the vision of providing quality diagnostic services at affordable prices, Thyrocare has become a prominent player in the healthcare diagnostics industry. The company specializes in biochemical tests and profiles that are used for monitoring health, diagnosis of diseases, and treatment monitoring. Thyrocare's operations are supported by its state-of-the-art Central Processing Laboratory in Navi Mumbai, which is one of the largest in the world. The company has been at the forefront of adopting technology to streamline its processes and improve service delivery. Recent developments include expanding its testing services to cover a broader range of health conditions and enhancing its digital platforms to improve customer engagement and service delivery.
Revenue
For the fourth quarter of fiscal year 2025, Thyrocare Technologies Ltd reported a total income of ₹157.74 crores. This reflects a decline of 7.2% when compared to the third quarter of fiscal year 2025, where the total income was ₹169.93 crores. However, when looking at the year-over-year comparison, total income increased by 13.0% from ₹139.58 crores in the fourth quarter of fiscal year 2024. This year-over-year growth indicates the company's ability to increase its revenue over the past year, despite the quarter-over-quarter decline observed in the most recent quarter.
Profitability
The company's profitability, as indicated by the Profit After Tax (PAT), was ₹17.18 crores in Q4FY25, showing a decrease of 9.3% from the previous quarter's PAT of ₹18.95 crores. However, compared to the same quarter in the previous year (Q4FY24), there is an increase of 37.6% from ₹12.49 crores. The Earnings Per Share (EPS) for Q4FY25 was ₹3.50, which is a slight decrease of 2.8% from ₹3.60 in Q3FY25 but marks a substantial increase of 45.8% from ₹2.40 in Q4FY24. Despite the quarter-over-quarter decrease, the year-over-year increase in both PAT and EPS shows significant improvement in profitability terms over the past year.
Operating Metrics
Thyrocare's total expenses for Q4FY25 were ₹134.62 crores, which is a reduction of 5.1% from ₹141.85 crores in Q3FY25. When compared year-over-year, total expenses increased by 9.8% from ₹122.66 crores in Q4FY24. This indicates a careful management of operating expenses in the latest quarter, leading to reduced costs on a quarterly basis. The Profit Before Tax (PBT) for Q4FY25 was ₹23.12 crores, down 17.7% from ₹28.08 crores in Q3FY25, but up 36.6% from ₹16.92 crores in Q4FY24. The tax expense for the quarter was ₹5.72 crores, marking a significant decrease of 36.2% from ₹8.97 crores in the previous quarter, but an increase of 20.4% from ₹4.75 crores in the same quarter of the prior year. These metrics highlight the shifts in cost structures and the impact on profitability from both a quarterly and yearly perspective.
